News headlines about Humana (NYSE:HUM) have been trending somewhat positive on Friday, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Humana earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the insurance provider an impact score of 45.8536807827886 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- The Fifth Circuit Takes a Fresh Look at ERISA Benefit Claims Review Standard (lexology.com)
- Humana Inc (HUM) to Issue Dividend Increase – $0.50 Per Share (americanbankingnews.com)
- Analysts Anticipate Humana Inc (HUM) to Post $3.21 Earnings Per Share (americanbankingnews.com)
- Stock for Low Risk Taking Investors: Humana Inc. (HUM) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Humana to pay $2.5M to resolve alleged pay discrimination – Louisville Business First (bizjournals.com)
A number of research analysts have weighed in on HUM shares. Leerink Swann raised their target price on shares of Humana from $280.00 to $300.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $297.00 target price on the stock in a research note on Monday, January 15th. ValuEngine lowered shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Cantor Fitzgerald reissued a “hold” rating and issued a $250.00 target price on shares of Humana in a research note on Wednesday, February 7th. Finally, Oppenheimer raised their target price on shares of Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Eight equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Humana currently has an average rating of “Buy” and a consensus target price of $270.47.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Humana had a net margin of 4.55% and a return on equity of 16.13%. The firm had revenue of $13.19 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same quarter last year, the firm earned $2.34 EPS. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. equities research analysts forecast that Humana will post 13.84 earnings per share for the current fiscal year.
Humana announced that its board has authorized a stock buyback plan on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend is Wednesday, March 28th. This is an increase from Humana’s previous quarterly dividend of $0.40. Humana’s dividend payout ratio (DPR) is 9.59%.
In related news, CEO Bruce D. Broussard sold 14,075 shares of Humana stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $274.32, for a total value of $3,861,054.00. Following the completion of the sale, the chief executive officer now owns 113,896 shares in the company, valued at approximately $31,243,950.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Cynthia H. Zipperle sold 1,196 shares of Humana stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $273.33, for a total transaction of $326,902.68. Following the completion of the sale, the senior vice president now owns 7,771 shares of the company’s stock, valued at approximately $2,124,047.43. The disclosure for this sale can be found here. Insiders sold a total of 31,660 shares of company stock valued at $8,668,218 in the last quarter. 0.60% of the stock is owned by insiders.
WARNING: This article was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3294153/humana-hum-getting-somewhat-favorable-press-coverage-study-shows.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.